Chemomab Therapeutics's market cap is currently $33.38M. The company's EPS TTM is $-0.992; its P/E ratio is ―; Chemomab Therapeutics is scheduled to report earnings on March 6, 2025, and the estimated EPS forecast is $-0.06. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Gross Profit	$ -66.83K	$ -57.77K	$ -34.02K	$ -80.00K	$ -281.91K
Operating Income	$ -25.46M	$ -28.53M	$ -12.40M	$ -5.97M	$ -19.61M
EBITDA	$ -25.39M	$ -28.48M	$ -12.33M	$ -5.95M	$ -26.92M
Net Income	$ -24.22M	$ -27.65M	$ -12.55M	$ -5.93M	$ -27.21M
Balance Sheet
Cash & Short-Term Investments	$ 19.78M	$ 39.89M	$ 61.16M	$ 11.70M	$ 17.58M
Total Assets	$ 22.15M	$ 43.06M	$ 64.35M	$ 12.48M	$ 19.76M
Total Debt	$ 392.00K	$ 214.00K	$ 343.00K	$ 428.00K	$ 1.12M
Net Debt	$ -8.90M	$ -13.30M	$ -14.34M	$ -11.25M	$ -16.46M
Total Liabilities	$ 5.15M	$ 6.84M	$ 2.89M	$ 1.67M	$ 4.85M
Stockholders' Equity	$ 17.00M	$ 36.22M	$ 61.47M	$ 10.80M	$ 14.91M
Cash Flow
Free Cash Flow	$ -23.61M	$ -20.44M	$ -12.61M	$ -5.28M	$ -16.61M
Operating Cash Flow	$ -23.61M	$ -20.37M	$ -12.37M	$ -5.24M	$ -16.51M
Investing Cash Flow	$ 15.88M	$ 19.53M	$ -45.19M	$ -62.00K	$ -95.31K
Financing Cash Flow	$ 3.50M	$ -808.00K	$ 61.07M	$ 4.75M	$ 26.71M

Currency in USD

Chemomab Therapeutics Earnings and Revenue History

Income Statement >

Chemomab Therapeutics Debt to Assets

Balance Sheet >

Chemomab Therapeutics Cash Flow

Cash Flow >

Chemomab Therapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing